Compare Goldman Sachs Group Inc (GS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goldman Sachs Group Inc vs GeneDx Holdings Corp — how do they compare? Goldman Sachs Group Inc trades at $1,037 (market cap $301.19B), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: Goldman Sachs Group Inc is far larger — about 123.4× GeneDx Holdings Corp's market cap, and Goldman Sachs Group Inc pays a 1.93% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| GS | WGS | |
|---|---|---|
Market Cap | $301.19B | $2.44B |
Volume | 2,592,735 | — |
Sector | Financials | Technology |
52-Week High | $1.15K | $167.51 |
52-Week Low | $715.95 | $34.51 |
Dividend Yield | 1.93% | — |
Enterprise Value | — | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $1,034.51, down 0.49% on the day, with a neutral technical signal and strong fundamental performance. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $20.98 surpassing the $14.47 estimate. Revenue growth is robust, rising to $58.28 billion in 2025, and net income margin expanded to 31.68%. The company is positioned to benefit from a surge in investment banking activity, including leading high-profile IPOs like Anthropic.
The outlook is positive given earnings momentum and strategic positioning in key deals, but risks include volatile cash flows and high leverage. Analyst consensus is a Buy with a $1,160 price target, implying potential upside. Investors should weigh strong profitability against macroeconomic sensitivity and balance sheet pressures.
GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.
Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
